A Phase II Pilot Study of Disulfiram and Copper Gluconate in Patients With Metastatic Pancreatic Cancer and Rising CA-19-9 Levels While Receiving Abraxane-Gemcitabine or FOLFIRINOX or Single-Agent Gemcitabine
Phase: PHASE2
Conditions: Metastatic Pancreatic Cancer
Sponsor: HonorHealth Research Institute

20182808 
IRB Approved at the 
Protocol Level 
May 07, 2019 
CAN-203 
A Phase II Pilot Study of Disulfiram and Copper Gluconate in 
Patients with Metastatic Pancreatic Cancer and Rising CA-19-9 
Levels While Receiving Abraxane-Gemcitabine or FOLFIRINOX or 
Single-Agent Gemcitabine 
IND#: 139916 
Version: 4.0 
Version Date: 19 APR 2019 
SPONSOR 
Cantex Pharmaceuticals, Inc. 
1792 Bell Tower Lane 
Weston, FL 33326 
NCT03714555